Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.56 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KCNJ6 | P48051 | 6/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.48 |
| ▸ | KCNJ5 | P48544 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451752 | 1.00 | ALDH1A1 (0.56) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL4639725 | 0.85 | L3MBTL1 (0.63) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL16364899 | 0.82 | ALDH1A1 (0.55) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL9320508 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP3A4L3MBTL1LMNANPC1 | |
| SCHEMBL636186 | 0.79 | L3MBTL1 (0.55) | ALDH1A1CYP3A4L3MBTL1LMNANPC1 | |
| SCHEMBL8936354 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP3A4ALOX15L3MBTL1CASP1 | |
| SCHEMBL17774585 | 0.79 | ALDH1A1 (0.43) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL22409045 | 0.79 | GSTO1 (0.50) | ALDH1A1PDE2APDE5ACYP3A4ALOX15 | |
| SCHEMBL1913490 | 0.79 | CA1 (0.44) | ALDH1A1CYP3A4ALOX15L3MBTL1CASP1 | |
| SCHEMBL1406184 | 0.78 | L3MBTL1 (0.70) | ALDH1A1CYP3A4L3MBTL1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| WO-2022032144-A1 | SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-9067894-B1 | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest | VANDERBILT UNIVERSITY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067894-B1 | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest | VANDERBILT UNIVERSITY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067894-B1 | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest | VANDERBILT UNIVERSITY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9006277-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20110319447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8053456-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053456-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | disclosed |
| EP-0372315-B1 | Reactive dyes based on copper formazane | BASF AG (DE) | 1994-01-26 | — | — | EP | disclosed |
| US-5245020-A | Reactive dyes with two or three nitrogen-containing haloheterocycles as reactive system | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-14 | — | — | US | disclosed |
| US-5149789-A | Triazine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-22 | — | — | US | disclosed |
| US-5041540-A | For dyeing or printing hydroxyl- or nitrogen-containing substrates | BASF AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0391264-A1 | Reactive dyes with two or three halogen-N-heterocycles as reactive groups | BASF Aktiengesellschaft (DE) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | HSP90AB1, HSP90AB2P, HSP90B1 | ALDH1A1 1933/4885PDE2A 1968/4885PDE5A 2376/4885 |
| US-20110319447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 2165/4885PDE2A 2045/4885PDE5A 1956/4885 |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALDH1A1 2165/4885PDE2A 2045/4885PDE5A 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.